Vanda Pharmaceuticals sets 2025 bonuses, 2026 salaries, and grants RSUs/PSUs to executives

Vanda Pharmaceuticals Inc.

CEO Polymeropoulos gets $834,326 2025 bonus; 2026 base $994,625, target bonus 80%.
Other NEOs 2025 bonuses $272k-$282k; 2026 base $576,735-$596,990, target 45%.
RSUs: 525,000 to CEO, 125,000 to each of four other NEOs; vest in 4 equal annual installments.
PSUs: target 175,000 (CEO), 40,000 (others); payout 0%-150% based on relative TSR vs Nasdaq Biotech Index over 3 years.
Compensation Committee used Willis Towers Watson peer analysis in determining compensation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.